Identification of BMS-200475 as a Novel and Potent Inhibitor of Hepatitis B Virus Replication
April 11, 1997
R.J. Colonno, et al
BMS-200475 was first reported as having rather limited antiviral activity against herpesviruses. At ICAAC (September 1996), its very potent activity against human hepatitis B virus (HBV) was announced. At this meeting (ICAR), there were, in addition, 3 poster presentations.
BMS-200475, a Novel Carbocyclic 2-Deoxyguanosine Analog with Potent and
Selective Anti-Hepatitis B Virus Activity in Vitro
BMS-200475, a New Anti-Hepatitis B Compound; Metabolic Studies and
Comparison with 3TC, Penciclovir, and Lobucavir
Carbocyclic Guanosine Nucleoside BMS-200475 Treatment Inhibits Woodchuck Hepatitis Virus (WHV) Viremia in WHV-Carriers
E.V. Genovesi, et al
BMS-200475 is a chiral compound, that means that its mirror image (enantiomer) is a different compound (as a left hand differs from a right hand). Interestingly the enantiomer has poor activity against HBV. The chemical synthesis gives BMS-200475 with good enantiomeric purity (>99%) in 20 g batches.
This article was provided by TheBodyPRO. It is a part of the publication The 10th Annual International Society For Antiviral Research Conference.